Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND AND AIMS: Whether entecavir (ETV) and tenofovir disoproxil fumarate (TDF) differentially affect relapse and outcomes following treatment discontinuation across different patient subpopulations remains unclear. We aimed to compare rates of off-therapy hepatitis B surface antigen (HBsAg) loss, virological and clinical relapse, and retreatment between chronic hepatitis B (CHB) patients who discontinued TDF or ETV therapy.
METHODS: This study included 1402 virally suppressed CHB patients who stopped either ETV (n = 981) or TDF (n = 421) therapy between 2001 and 2020 from 13 participating centers across North America, Europe, and Asia. All patients were hepatitis B e antigen-negative at treatment discontinuation. Inverse probability of treatment weighting was used to balance the treatment groups. Outcomes were analyzed using survival methods.
RESULTS: During a median off-treatment follow-up of 18 months, HBsAg loss occurred in 96 (6.8%) patients overall. Compared with ETV, TDF was associated with a higher rate of HBsAg loss (P = .03); however, the association was no longer significant after statistical adjustment (P = .61). Virological relapse occurred earlier among TDF-treated patients (P < .01); nonetheless, rates became comparable after the first year off therapy (P = .49). TDF was significantly associated with a higher clinical relapse rate than ETV throughout follow-up (P < .01). The development of a virological or clinical relapse did not affect the rate of HBsAg loss. Retreatment rates were not significantly different between the treatment groups.
CONCLUSIONS: TDF and ETV have differential relapse patterns but are associated with similar rates of HBsAg loss and retreatment following discontinuation. Finite therapy can be considered for CHB patients on either TDF or ETV therapy.
| Errataetall: |
CommentIn: Clin Gastroenterol Hepatol. 2023 May;21(5):1380. - PMID 35985637 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association - 21(2023), 6 vom: 01. Juni, Seite 1513-1522.e4 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Choi, Hannah S J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5968Y6H45M |
|---|
| Anmerkungen: |
Date Completed 29.05.2023 Date Revised 30.05.2023 published: Print-Electronic CommentIn: Clin Gastroenterol Hepatol. 2023 May;21(5):1380. - PMID 35985637 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cgh.2022.07.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343836777 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343836777 | ||
| 003 | DE-627 | ||
| 005 | 20231226021359.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cgh.2022.07.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1146.xml |
| 035 | |a (DE-627)NLM343836777 | ||
| 035 | |a (NLM)35863683 | ||
| 035 | |a (PII)S1542-3565(22)00672-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Choi, Hannah S J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.05.2023 | ||
| 500 | |a Date Revised 30.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Clin Gastroenterol Hepatol. 2023 May;21(5):1380. - PMID 35985637 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND AND AIMS: Whether entecavir (ETV) and tenofovir disoproxil fumarate (TDF) differentially affect relapse and outcomes following treatment discontinuation across different patient subpopulations remains unclear. We aimed to compare rates of off-therapy hepatitis B surface antigen (HBsAg) loss, virological and clinical relapse, and retreatment between chronic hepatitis B (CHB) patients who discontinued TDF or ETV therapy | ||
| 520 | |a METHODS: This study included 1402 virally suppressed CHB patients who stopped either ETV (n = 981) or TDF (n = 421) therapy between 2001 and 2020 from 13 participating centers across North America, Europe, and Asia. All patients were hepatitis B e antigen-negative at treatment discontinuation. Inverse probability of treatment weighting was used to balance the treatment groups. Outcomes were analyzed using survival methods | ||
| 520 | |a RESULTS: During a median off-treatment follow-up of 18 months, HBsAg loss occurred in 96 (6.8%) patients overall. Compared with ETV, TDF was associated with a higher rate of HBsAg loss (P = .03); however, the association was no longer significant after statistical adjustment (P = .61). Virological relapse occurred earlier among TDF-treated patients (P < .01); nonetheless, rates became comparable after the first year off therapy (P = .49). TDF was significantly associated with a higher clinical relapse rate than ETV throughout follow-up (P < .01). The development of a virological or clinical relapse did not affect the rate of HBsAg loss. Retreatment rates were not significantly different between the treatment groups | ||
| 520 | |a CONCLUSIONS: TDF and ETV have differential relapse patterns but are associated with similar rates of HBsAg loss and retreatment following discontinuation. Finite therapy can be considered for CHB patients on either TDF or ETV therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic Hepatitis B | |
| 650 | 4 | |a Entecavir | |
| 650 | 4 | |a Nucleos(T)Ide Analogue Withdrawal | |
| 650 | 4 | |a Off-Therapy Outcomes | |
| 650 | 4 | |a Tenofovir | |
| 650 | 7 | |a Tenofovir |2 NLM | |
| 650 | 7 | |a 99YXE507IL |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Hepatitis B Surface Antigens |2 NLM | |
| 650 | 7 | |a entecavir |2 NLM | |
| 650 | 7 | |a 5968Y6H45M |2 NLM | |
| 650 | 7 | |a DNA, Viral |2 NLM | |
| 700 | 1 | |a Hirode, Grishma |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Chien-Hung |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Tung-Hung |e verfasserin |4 aut | |
| 700 | 1 | |a Seto, Wai-Kay |e verfasserin |4 aut | |
| 700 | 1 | |a Van Hees, Stijn |e verfasserin |4 aut | |
| 700 | 1 | |a Papatheodoridi, Margarita |e verfasserin |4 aut | |
| 700 | 1 | |a Lens, Sabela |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Grace L H |e verfasserin |4 aut | |
| 700 | 1 | |a Brakenhoff, Sylvia M |e verfasserin |4 aut | |
| 700 | 1 | |a Chien, Rong-Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Feld, Jordan J |e verfasserin |4 aut | |
| 700 | 1 | |a Sonneveld, Milan J |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Henry L Y |e verfasserin |4 aut | |
| 700 | 1 | |a Forns, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Papatheodoridis, George V |e verfasserin |4 aut | |
| 700 | 1 | |a Vanwolleghem, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Yuen, Man-Fung |e verfasserin |4 aut | |
| 700 | 1 | |a Hsu, Yao-Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Kao, Jia-Horng |e verfasserin |4 aut | |
| 700 | 1 | |a Cornberg, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Hansen, Bettina E |e verfasserin |4 aut | |
| 700 | 1 | |a Jeng, Wen-Juei |e verfasserin |4 aut | |
| 700 | 1 | |a Janssen, Harry L A |e verfasserin |4 aut | |
| 700 | 0 | |a RETRACT-B study group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association |d 2003 |g 21(2023), 6 vom: 01. Juni, Seite 1513-1522.e4 |w (DE-627)NLM147178851 |x 1542-7714 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g number:6 |g day:01 |g month:06 |g pages:1513-1522.e4 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cgh.2022.07.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |e 6 |b 01 |c 06 |h 1513-1522.e4 | ||